combination of parp inhibitor and temozolomide to suppress chordoma progression

Chordoma, a malignant bone cancer, is highly resistant to conventional therapeutic approaches; this greatly limits radio- and chemotherapeutic options and disease management. in the present study, we investigated three patient-derived chordoma cell lines to elucidate the molecular mechanism of resistance to therapeutics. an in vitro high-throughput chemical screening assay and an in vivo xenograft model were used to identify novel chemosensitizers for chordoma. we found that patient-derived chordoma cell lines recapitulated disease phenotypes, which were highlighted by robust resistance to medical therapy manifested as lack of dna damage accumulation. mechanistically, the parp dna repair pathway was found to play a central role in this resistance. chemical screening confirmed that parp inhibitors could strikingly enhance temozolomide (tmz) therapy in chordoma cells. combining the fda-approved parp inhibitor, olaparib, with chemotherapeutics not only potentiated dna damage accumulation, cell cycle arrest, and apoptosis in vitro but also suppressed chordoma xenograft expansion in vivo. we conclude that combining parp inhibition with tmz could be an effective therapeutic approach for the clinical management of chordoma.